Ratchaphruek Hospital Public Company Limited (RPH) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Ratchaphruek Hospital Public Company Limited THB 5.10, price THB 4.86, upside +4.9%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ratchaphruek Hospital Public Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3.83 THB – 6.26 THB · fair‑value band 3.47 THB – 7.15 THB · the 4.86 THB price screens below the 5.10 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Ratchaphruek Hospital Public Company in your weekly email
Every Wednesday you see whether Ratchaphruek Hospital Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ratchaphruek Hospital Public Company Limited engages in the hospital business under the Ratchaphruek Hospital name in Thailand.
Show more
Ratchaphruek Hospital Public Company Limited engages in the hospital business under the Ratchaphruek Hospital name in Thailand. The company offers medical services in the field of internal medicine, such as diabetes and endocrine, dermatology, neurology, hematology, pulmonary, rheumatology, gastroenterology, nephrology, and cardiology; as well as operates stroke, breast, and hearing and balance medical centers. It also provides surgery services, including general, men health related, urological surgery, and colorectal surgery services; and pediatric, speech therapy, pediatric cardiology, and developmental and behavioral services. In addition, the company offers orthopedics and pediatric orthopedic services; otorhinolaryngology, nasal, sinus, allergy, and sleep medicine services; ophthalmology, retina and vitreous, and pediatrics ophthalmology services; and obstetrics and gynecology, gynecological laparoscopy, and maternal-fetal medicine services. Further, it provides health check-up, dental, prosthodontics, and orthodontics services; anesthesiology, emergency medicine, rehabilitation medicine, and diagnostic radiology services; and sells medicines and medical supplies. The company was formerly known as Sithan Karnpat Company Limited and changed its name to Ratchaphruek Hospital Public Company Limited in September 2016. Ratchaphruek Hospital Public Company Limited was incorporated in 1993 and is based in Khon Kaen, Thailand.
Stock analysis
Ratchaphruek Hospital Public Company Limited (RPH) currently trades at 4.86 THB, while our model-based Fair Value estimate is 5.10 THB, implying the stock looks roughly 4.7% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 6.81 THB per share, and 14 of the 26 models we run sit above the 4.86 THB price.
Bear case: the Asset-Based group reads lowest at 2.17 THB, and 12 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 3.47 THB (bear) to 7.15 THB (bull), the price of 4.86 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ratchaphruek Hospital Public Company Limited reported revenue of 1.2B THB in FY2025 versus 1.4B THB in FY2021, a compound −4.8%/yr. Reported net income was 182M THB in FY2025, compounding −18.0%/yr from FY2021.
Key figures
Market cap 2.6B THB (≈ $77.5M) · P/E ratio 15.2 · P/S ratio 2.38 · EPS (TTM) 0.3200 THB · Dividend yield 5.8% · Net margin 15.7% · Return on equity 9.6% · Return on assets (EBIT) 14.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 4% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 5%, RPH screens richer than that median.
Fair Value models
Bear 3.47 THBFair Value 5.10 THBBull 7.15 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0294 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
Start year 2020 (pandemic). Over 10 years: +11.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)5.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14% vs 14%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 18%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about +11.6% a year for the price.
Compare Ratchaphruek Hospital Public Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside+5% · Above median
Profitability
Return on equity (TTM)10% · Above median
Return on assets7% · Above median
Net margin (TTM)15% · Top 25%
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth−5% · Bottom 25%
Dividend yield (TTM)5.8% · Top 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ratchaphruek Hospital Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/RPH
Frequently asked questions
Is Ratchaphruek Hospital Public Company Limited (RPH) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 5.10 THB versus a price of 4.86 THB, about +5% upside (fairly valued).
What is the fair value of RPH?
Our model-based fair value for Ratchaphruek Hospital Public Company Limited is 5.10 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 4.86 THB.
What is the quality score of RPH?
Ratchaphruek Hospital Public Company Limited has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ratchaphruek Hospital Public Company Limited (RPH)?
Our model-based price target is the fair value of 5.10 THB (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 3.47 THB, optimistic scenario 7.15 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Ratchaphruek Hospital Public Company Limited stock forecast for 2026?
Our models put fair value at 5.10 THB, about +5% upside versus a price of 4.86 THB (fairly valued). Cautious scenario 3.47 THB, optimistic scenario 7.15 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Ratchaphruek Hospital Public Company Limited (RPH)?
Ratchaphruek Hospital Public Company Limited reported trailing-twelve-month revenue of about 1.1B THB (latest available figure, as of Sep 24, 2026).
Does Ratchaphruek Hospital Public Company Limited pay a dividend?
Ratchaphruek Hospital Public Company Limited currently shows a dividend yield of about 5.76% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Ratchaphruek Hospital Public Company Limited (RPH)?
For today's price to be fair in a discounted-cash-flow model, Ratchaphruek Hospital Public Company Limited would have to grow free cash flow by +13.0 % per year for five years (discount rate 14.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of RPH use?
Our models discount Ratchaphruek Hospital Public Company Limited at 14.6 %: a base by market capitalisation (micro), country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ratchaphruek Hospital Public Company Limited that is +13.0 % per year a year over ten years, using the same discount rate (14.6 %) and the same formula as our fair value.
How much growth has Ratchaphruek Hospital Public Company Limited (RPH) delivered so far?
Over the past 5 years revenue at Ratchaphruek Hospital Public Company Limited grew +7.8 % a year. The price currently implies +13.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ratchaphruek Hospital Public Company Limited (RPH) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Ratchaphruek Hospital Public Company Limited (+13.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ratchaphruek Hospital Public Company Limited (RPH)?
The free-cash-flow yield on the price is 6.51 %: that much free cash flow Ratchaphruek Hospital Public Company Limited produces per unit of market value. When it exceeds the discount rate of our models (14.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ratchaphruek Hospital Public Company Limited (RPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ratchaphruek Hospital Public Company Limited it is 5.10 THB per share (as of Sep 24, 2026), against a price of 4.86 THB. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Ratchaphruek Hospital Public Company Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RPH trades below its calculated fair value: price 4.86 THB, fair value 5.10 THB, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RPH?
No. The price is what the market pays today (4.86 THB); the fair value is what the company's own numbers justify (5.10 THB). For Ratchaphruek Hospital Public Company Limited the two are 0.2400 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Ratchaphruek Hospital Public Company Limited worth?
The market values Ratchaphruek Hospital Public Company Limited at about 2.6B THB (market capitalisation, as of Sep 24, 2026). Per share that is 4.86 THB; our models calculate a fair value of 5.10 THB per share.
What do the bullish and bearish scenarios say about RPH?
Our models span a range for Ratchaphruek Hospital Public Company Limited: cautious scenario 3.47 THB, base 5.10 THB, optimistic 7.15 THB per share (as of Sep 24, 2026, price 4.86 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RPH?
Ratchaphruek Hospital Public Company Limited trades at a price-to-earnings ratio of 15.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5.10 THB is built from several models across several years. Other multiples: P/B 1.5, P/S 2.3, EV/EBITDA 8.2.
How solid is the balance sheet of Ratchaphruek Hospital Public Company Limited (RPH)?
Balance-sheet figures for Ratchaphruek Hospital Public Company Limited (as of Sep 24, 2026): return on equity 9.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is RPH from its 52-week high?
Ratchaphruek Hospital Public Company Limited trades at 4.86 THB, about 4% below its 52-week high of 5.05 THB and 4% above the low of 4.69 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 5.10 THB is for.
Which stocks are comparable to Ratchaphruek Hospital Public Company Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ratchaphruek Hospital Public Company Limited stock attractive at the current price?
The data as of Sep 24, 2026: price 4.86 THB, calculated fair value 5.10 THB (+5%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RPH calculated?
We run Ratchaphruek Hospital Public Company Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5.10 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Ratchaphruek Hospital Public Company Limited currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ratchaphruek Hospital Public Company Limited (RPH)?
The closing price on Sep 24, 2026 was 4.86 THB. Our model-based fair value is 5.10 THB, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ratchaphruek Hospital Public Company Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (3.47 THB to 7.15 THB) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Ratchaphruek Hospital Public Company Limited (RPH) come from?
Earnings per share at Ratchaphruek Hospital Public Company Limited grew +14.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.9 %, EBIT margin +0.1 %, tax rate +0.0 %, residual (interest, one-offs) +1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ratchaphruek Hospital Public Company Limited
How large is the market capitalisation of Ratchaphruek Hospital Public Company Limited (RPH)?
The market capitalisation of Ratchaphruek Hospital Public Company Limited is 2.6B THB (≈ $77.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ratchaphruek Hospital Public Company Limited (RPH)?
The price-to-sales ratio of Ratchaphruek Hospital Public Company Limited is 2.38 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ratchaphruek Hospital Public Company Limited (RPH)?
Earnings per share at Ratchaphruek Hospital Public Company Limited are 0.3200 THB (price ÷ EPS = P/E 15.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ratchaphruek Hospital Public Company Limited (RPH)?
The dividend yield of Ratchaphruek Hospital Public Company Limited is 5.8% (payout 87.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ratchaphruek Hospital Public Company Limited (RPH)?
The net margin of Ratchaphruek Hospital Public Company Limited is 15.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ratchaphruek Hospital Public Company Limited (RPH)?
The return on equity (ROE) of Ratchaphruek Hospital Public Company Limited is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ratchaphruek Hospital Public Company Limited (RPH)?
On an EBIT basis the return on assets of Ratchaphruek Hospital Public Company Limited is 14.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ratchaphruek Hospital Public Company Limited (RPH)?
The operating margin of Ratchaphruek Hospital Public Company Limited is 14.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ratchaphruek Hospital Public Company Limited (RPH)?
Revenue at Ratchaphruek Hospital Public Company Limited is growing −5.4% versus a year earlier (3y avg −4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ratchaphruek Hospital Public Company Limited (RPH)?
Earnings per share at Ratchaphruek Hospital Public Company Limited are growing −30.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ratchaphruek Hospital Public Company Limited (RPH) hold?
Ratchaphruek Hospital Public Company Limited holds more cash than debt, 277M THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ratchaphruek Hospital Public Company Limited in the live analysis
One click puts Ratchaphruek Hospital Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
